Summary
A case history is reported or renal failure during and after treatment with carboplatin for 3 days, total dose 750 mg/m2, in a conditioning regimen prior to autologous bone marrow transplantation. Pretreatment renal function was compromised after nephrectomy and chemotherapy with cisplatin. A decrease in glomerular filtration rate concurred with a decreased in excretion of platinum in the urine and an increase in urinary beta 2 microglobulin. Treatment with high-dose carboplatin in patients with impaired renal function and previous treatment with cisplatin may lead to further loss of renal function.
This is a preview of subscription content, log in via an institution to check access.
References
Calvert AH, Harland SJ, Newell DR etal. (1982) Early clinical studies with cis-diammine-1,1 cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 9:140–147
Canetta R, Rozencweig M, Carter SK (1985) Carboplatin: the clinical spectrum to date. Cancer Treat Rev 12 (suppl A):125–136
Curt GA, Grygiel JJ, Corden BJ et al. (1983) A phase I and pharmacokinetic study of diamminecyclobutanedicarboxylatoplatinum (NSC 241240). Cancer Res 43:4470–4473
Egorin MJ, van Echo DA, Tipping SJ et al. (1984) Pharmacokinetics and dosage reduction of cis-diammine (1,1-cyclobutanedicarboxylato) platinum in patients with impaired renal function. Cancer Res 44:5432–5438
Ethinger LJ, Siegel SE, Baum ES, Moel DI, Gaynon PS (1984) Phase I pediatric trial of cis-diammine-1,1 cyciobutane dicarboxylate platinum II (NSC 241240, CBDCA). Proc ASCO 3:44
Evans BD, Raju KS, Calvert AH, Harland SJ, Wiltshaw E (1983) Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma. Cancer Treat Rep 67:997–1000
Gaver RC, Deep G (1986) High performance liquid chromatographic procedures for the analysis of carboplatin in human plasma and urine. Cancer Chemother Pharmacol 16:201–206
Gore ME, Calvert AH, Smith IE (1987) High dose carboplatin in the treatment of lung cancer and mesothelioma: a phase I dose escalation study. Eur J Cancer Clin Oncol 23:1391–1397
Harland SJ, Newell DR, Siddik ZH, Chadwick R, Calvert AH, Harrap KR (1984) Pharmacolinetics of cis-diammine-1,1 cyclobutane dicarboxylate platinum (II) in patients with normal and impaired renal function. Cancer Res 44:1693–1697
Kaplan S, Joss R, Sena C, Goldhirsch A, Cattneo M, Cavalli F (1983) Phase I trials of cis-diammine-1,1-cyclobutane dicarboxylate platinum (II) (CBDCA) in solid tumors. Proc Am Assoc Cancer Res 24:132
Koeller JM, Trump DL, Tutsch KD, Earhart RH, Davis TE, Tormey DC (1986) Phase I clinical trial and pharmacolinetics of carboplatin (NSC 241240) by single monthly 30 min infusion. Cancer 57:222–225
Leroy AF, Wehling, ML, Sponseller HL et al. (1977) Analysis of platinum in biological materials by flameless atomic absorption spectrometry. Biochem Med 13:184–191
Offerman JJG, Hollema H, Elema JD, Schraffordt Koops H, de Vries EGE (1985) NO--6 induced acute renal failure. A case report. Cancer 56:1511–1514
Reece PA, Stafford I, Russell J, Gill PG (1986) Reduced ability to clear ultrafilterable platinum with repeated courses of cisplatin. J Clin Oncol 4:1392–1398
Rose WC, Schurig JE (1985) Preclinical antitumor and toxicologic profile of carboplatin. Cancer Treat Rev 12 (suppl A):1–19
Van Barneveld PWC, Sleijfer DTh, Van der Mark ThW et al. (1984) Influence of platinum-induced renal toxicity on bleomycin-induced pulmonary toxicity in patients with disseminated testicular carcinoma. Oncology 41:4–7
Van Echo DA, Egorin MJ, Whitacre MY, Olman EA, Aisner J (1984) Phase I clinical and pharmacologic trial of carboplatin daily for 5 days. Cancer Treat Rep 68:1103–1114
Von Hoff (1987) Whither carboplatin? A replacement for or an alternative to cisplatin? (Editorial). J Clin Oncol 5:169–171
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mulder, P.O.M., Sleijfer, D.T., de Vries, E.G.E. et al. Renal dysfunction following high-dose carboplatin treatment. J Cancer Res Clin Oncol 114, 212–214 (1988). https://doi.org/10.1007/BF00417840
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00417840